Oncoinvent raises $3.7M for cancer drug

Drug Discovery | Oslo, Norway | PE Growth

Oncoinvent, a Stockholm-based startup developing a treatment for colorectal cancer, has collected 40 million Norwegian kroner (around €3.66 million) in a round lead by Hadea Ventures. Existing investors including CGS Holding, Alpine Capital, Artal and Sciencons also took part in the round. The new funding will be used to fund clinical trials of Oncoinvent's lead drug, Radspherin.

Investors